January 6, 2023 07:12 AM ESTUpdated 11:09 AM

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ While an FDA ruling on Eisai and Biogen’s Alzheimer’s drug lecanemab is imminent, new Biogen CEO Chris Viehbacher is splitting the role of R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Bio­gen names de­vel­op­ment chief as it braces for lecanemab de­ci­sion; Zymeworks CMO is shown the door

Senior Editor

Editor

Sign up to read this article for free.

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door